AVTX Avalo Therapeutics, Inc.: institutional ownership and insider trading
134 funds reported holding $1.34B of Avalo Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net bought $685M, with 52 new positions and 27 funds selling out; over the last 12 months insiders bought $0 and sold $8.50M on the open market.
Famous investors holding AVTX
- Renaissance Technologies (Renaissance Technologies): $6.60M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $8.32M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $1.24M, 0.0% of the portfolio
Largest institutional holders of AVTX
- FMR LLC — $94.3M
- BlackRock, Inc. (BLK) — $80.7M
- Deep Track Capital, LP — $66.7M
- Caligan Partners LP — $58.5M
- TCG Crossover Management, LLC — $55.8M
- Affinity Asset Advisors, LLC — $53.6M
- STATE STREET CORP (STT, STT-PG) — $53.4M
- FARALLON CAPITAL MANAGEMENT, L.L.C. — $46.2M
- Point72 Asset Management, L.P. — $44.1M
- Avoro Capital Advisors LLC — $43.1M
Recent AVTX insider trades
- Sep 16, 2026: Sullivan Christopher Ryan sold 12,394 shares ($202K)
- Sep 10, 2026: Sullivan Christopher Ryan sold 10,185 shares ($179K)
- Aug 28, 2026: Doyle Mittie sold 679 shares ($13.6K)
- Aug 18, 2026: Sullivan Christopher Ryan sold 72,725 shares ($1.45M)
5%+ owners
- FMR LLC: 10.8% (Schedule 13G/A, filed Aug 7, 2026)
- Commodore Capital LP: 9.9% (Schedule 13G, filed Jun 18, 2026)
- TCG Crossover GP II, LLC: 7.9% (Schedule 13G, filed May 12, 2026)
- Deep Track Capital, LP: 6.9% (Schedule 13G/A, filed Aug 14, 2026)
- BlackRock, Inc.: 6.5% (Schedule 13G, filed Jul 27, 2026)
- RA Capital Management, L.P.: 6.3% (Schedule 13G/A, filed Aug 14, 2026)